#alkermes Tech News.
1 story in the last 7 days
The latest alkermes news, distilled by AI into sharp ~100-word summaries. ByteBrief tracks alkermes across dozens of tech sources and brings you only what matters, updated hourly. Tap any story for the full brief, or open the original source.
FinanceSeeking Alphaabout 5 hours ago
Alkermes Buy Rating on Avadel Deal and NT2 DataAlkermes maintains a Buy rating after acquiring Avadel Pharmaceuticals, adding LUMRYZ to its hypersomnolence portfolio with robust early sales. Positive phase 2 data for alixorexton in narcolepsy type 2 supports pipeline growth. The company projects full-year 2026 revenues between $1.73 and $1.84 billion from four approved drugs.
Summaries by ByteBrief